- Home
- DAWN vs AOSL Comparison
DAWN vs AOSL Comparison
Compare DAWN & AOSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- AOSL
- Stock Information
- Founded
- DAWN 2018
- AOSL 2000
- Country
- DAWN United States
- AOSL United States
- Employees
- DAWN N/A
- AOSL N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- AOSL Semiconductors
- Sector
- DAWN Health Care
- AOSL Technology
- Exchange
- DAWN Nasdaq
- AOSL Nasdaq
- Market Cap
- DAWN 1.2B
- AOSL 1.0B
- IPO Year
- DAWN 2021
- AOSL 2010
- Fundamental
- Price
- DAWN $12.43
- AOSL $34.08
- Analyst Decision
- DAWN Strong Buy
- AOSL Buy
- Analyst Count
- DAWN 7
- AOSL 3
- Target Price
- DAWN $36.17
- AOSL $38.67
- AVG Volume (30 Days)
- DAWN 782.5K
- AOSL 736.0K
- Earning Date
- DAWN 02-25-2025
- AOSL 02-05-2025
- Dividend Yield
- DAWN N/A
- AOSL N/A
- EPS Growth
- DAWN N/A
- AOSL N/A
- EPS
- DAWN N/A
- AOSL N/A
- Revenue
- DAWN $101,953,000.00
- AOSL $666,399,000.00
- Revenue This Year
- DAWN N/A
- AOSL $5.32
- Revenue Next Year
- DAWN $35.37
- AOSL $6.62
- P/E Ratio
- DAWN N/A
- AOSL N/A
- Revenue Growth
- DAWN N/A
- AOSL 4.12
- 52 Week Low
- DAWN $11.13
- AOSL $19.38
- 52 Week High
- DAWN $18.07
- AOSL $53.29
- Technical
- Relative Strength Index (RSI)
- DAWN 52.15
- AOSL 40.45
- Support Level
- DAWN $11.65
- AOSL $33.39
- Resistance Level
- DAWN $12.54
- AOSL $37.37
- Average True Range (ATR)
- DAWN 0.47
- AOSL 3.24
- MACD
- DAWN 0.02
- AOSL -0.33
- Stochastic Oscillator
- DAWN 80.53
- AOSL 5.20
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About AOSL Alpha and Omega Semiconductor Limited
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries.